

Program - June 28 (Thu.)

Heine's Hall (2F)

Educational Program with Support of ISTH

9:00 - 12:00

Chair: Claire McLintock National Women's Health, Auckland City Hospital, New Zealand
Yukio Ozaki Fuefuki Central Hospital, Japan

Management of Women with Inherited Bleeding Disorders in Pregnancy

Claire McLintock National Women's Health, Auckland City Hospital, New Zealand

Medical Patients From EXCLAIM to MARINER: Who would benefit from extended thromboprophylaxis?

Jeffrey Weitz Department of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Canada

VTE: How We Treat in 2018?

Walter Ageno Department of Medicine and Surgery, University of Insubria, Italy

Management of the Antiphospholipid syndrome

Tatsuya Atsumi Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Japan

Fundamental knowledge about platelet activation and platelet function tests

Katsue Suzuki-Inoue Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Japan

Luncheon Symposium (Stago)

New insights in haemostasis laboratory medicine

12:30 - 13:30

Moderator: François Depasse Diagnostica Stago, Asnières sur Seine, France

Thrombin generation: from research to clinical practice

François Depasse Diagnostica Stago, Asnières sur Seine, France

Elevated fibrin related markers in patients with disseminated intravascular coagulation

Hideo Wada Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Japan

Practical issues in coagulation testing of patients on direct oral anticoagulants

Heng Joo Ng Department of Haematology, Singapore General Hospital, Singapore

Educational Program with Support of WFH

14:00 - 17:00

Chair: H. Marijke van den Berg PedNet Haemophilia Research Foundation, The Netherlands
Akira Yoshioka Nara Medical University, Japan

New era for hemophilia, future never looked that bright

H. Marijke van den Berg PedNet Haemophilia Research Foundation, The Netherlands

Current status of hemophilia in Japan

Midori Shima Department of Pediatrics, Nara Medical University, Japan

Incidence of Factor VIII inhibitor in Previously Untreated Hemophilia A patients.

Ki-Young Yoo Foundation Clinic, Korea Hemophilia Foundation, Korea

Obesity and Overweight Impacts on Hemophilic Arthropathy

Yeu-Chin Chen Hemophilia Care & Research Center, Tri-Service General Hospital, National Defense Medical Center, Taiwan

Risk of deep Venous thrombosis after total knee arthroplasty in patients with haemophilia A

Kumiko Ono Department of Joint Surgery, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan

Afternoon Tea Seminar (Chugai Pharmaceutical Co., Ltd.)

Creation and Clinical Application of emicizumab

17:20 - 18:20

Chair: Renchi Yang Thrombosis and Hemostasis Center, Institute of Hematology and Blood Diseases Hospital, China

Katsuyuki Fukutake Laboratory Medicine, Tokyo Medical University, Japan

Creation of emicizumab

Takehisa Kitazawa Research Division, Chugai Pharmaceutical Co., Ltd., Japan

Novel Therapeutic Strategy for Patients with Hemophilia A (PwHA) with Inhibitors by emicizumab

Midori Shima Department of Pediatrics, Nara Medical University, Japan

Program - June 29 (Fri.)

Royton Hall AB (3F)

Special Lecture 1

11:10 - 12:00

Chair: Midori Shima Department of Pediatrics, Nara Medical University, Japan

Family History for Hemophilia is negative at diagnosis in the majority of new children with severe hemophilia A ; Data from the PedNet registry.

Inhibitor incidence in 1083 PUPs with severe haemophilia A treated with class Recombinant or with class Plasma-derived products is similar; Recent data from the PedNet study group

H. Marijke van den Berg PedNet Haemophilia Research Foundation, The Netherlands

Empress Hall (2F)

State of the Art Lecture 1

13:25 - 14:15

Chair: Mitsuru Murata Department of Laboratory Medicine, Keio University School of Medicine, Japan

Advances in the Treatment of Venous Thromboembolism

Jeffrey Weitz Department of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Canada

State of the Art Lecture 2

14:20 - 15:10

Chair: Yoshiaki Tomiyama Department of Blood Transfusion, Osaka University Hospital, Japan

Changes in the treatment of VTE and evidence from the real world

Walter Ageno Department of Medicine and Surgery, University of Insubria, Italy

Evening Seminar 1 (I. L. Japan Co., Ltd. (Werfen) / Bristol-Myers Squibb / Pfizer Inc.)

17:55 - 18:45

Chair: Tatsuya Atsumi Faculty of Medicine, Internal Medicine, Hokkaido University Hospital, Japan

Measurement of anti-factor Xa activity in Japanese patients on factor Xa inhibitor for non-valvular atrial fibrillation

Hiroyuki Osanai Department of Cardiovascular Medicine, Tosei General Hospital, Japan

Heine's Hall (2F)

Morning Symposium (Sanofi Genzyme)

7:50 - 8:50

Chair: Midori Shima Nara Medical University, Japan

Evolution of Hemophilia Care: Harnessing Molecular Targets Across the Entire Coagulation Cascade

Scott Dunkley Royal Prince Alfred Hospital, Australia

Faraizah Abdul Karim National Blood Centre, Malaysia

World Thrombosis Day Symposium

Increasing the awareness for thrombosis in Asia: challenges and WTD initiatives

9:00 - 11:00

Chair: Jeffrey Weitz Department of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Canada

Tetsumei Urano Department of Medical Physiology, Hamamatsu University School of Medicine, Japan

Program - June 29 (Fri.)

Cancer Associated Thrombosis

Pantep Angchaisuksiri Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

VTE in Obstetrics: risk assessment and prevention

Claire McLintock National Women's Health, Auckland City Hospital, New Zealand

Rising Incidence of Venous Thromboembolism in Asia

Lai Heng Lee Department of Hematology, Singapore General Hospital, Singapore

Risk Assessment for VTE in Hospitalized Patients

Jeffrey Weitz Department of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Canada

Luncheon Symposium (BioMarin Pharmaceutical Inc.)

Developments in AAV-mediated gene therapy

12:10 - 13:10

Chair: Midori Shima Nara Medical University, Japan

Ming-Ching Shen Changhua Christian Hospital, Taiwan

An introduction to AAV gene therapy

Gordon Vehar BioMarin Pharmaceutical Inc.

The principles and practice of AAV gene therapy studies

John Pasi Barts Health NHS Trust, London, UK

Symposium 1

Clinical laboratory testing provides protection for patients

13:20 - 15:20

Chair: Hideo Wada Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Japan

Tien Sim Leng Singapore General Hospital, Singapore

Antiphospholipid antibodies: assays and their implications

Kenji Oku Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University, Japan

Roles of blood coagulation markers for monitoring patients with infection-associated disseminated intravascular coagulation

Seiji Madoiwa Department of Clinical Laboratory Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan

Do we need thrombophilia tests for venous thromboembolism in Asians?

Ponlapat Rojnuckarin Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thailand

Global haemostatic assessment in current and future clinical practice

Heng Joo Ng Department of Haematology, Singapore General Hospital, Singapore

Symposium 2

Enlarging horizon of thrombosis and hemostasis: emerging new therapeutic targets

15:30 - 17:30

Chair: Yoshiaki Tomiyama Department of Blood Transfusion, Osaka University Hospital, Japan

Doyeun Oh Division of Hematology-oncology, Department of Internal Medicine, CHA University School of Medicine, Korea

The dual role of high-molecular-weight kininogen in host response to Gram-negative bacterial infection

Aizhen Yang Cyrus Tang Hematology Center, Soochow University, China

Program - June 29 (Fri.)

Looking beyond clotting: platelets beyond clotting.

Katsue Suzuki-Inoue Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Japan

Platelet-activating factor podoplanin: a potential therapeutic target of cancer progression and cancer-associated thrombosis

Ching-Ping Tseng Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taiwan

New treatment modalities of thrombotic thrombocytopenic purpura.

Masanori Matsumoto Department of Blood Transfusion Medicine, Nara Medical University, Japan

Antithrombin resistance: a unique inherited thrombophilia

Tetsuhito Kojima Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Japan

Crystal Room C (2F)

Oral Communication 1 - Hemophilia and Bleeding Disorders

9:00 - 10:00

Chair: Teruhisa Fujii Division of Blood Transfusion Services, Hiroshima University Hospital, Japan
Dong-Tsamn Lin National Taiwan University Hospital, Taiwan

O1-01 Gene skipping of Factor VIII Gene Transcript as a Future Treatment for Haemophilia A

Tiao Jim Y Western Australian Centre For Thrombosis And Haemostasis (WACTH) Murdoch University, Australia

O1-02 Genotype Analysis of Hemophilia B Patients in Taiwan

Chang Chia-Yau Hemophilia Center, Department of Pediatric Hematology/Oncology, Taipei Medical University Hospital, Taiwan

O1-03 Modified Thromboelastography- A method for the diagnosis and subtyping of von Willebrand disease

Ahammad Javed MANIPAL ACADEMY OF HIGHER EDUCATION, India

O1-04 High-dose dexamethasone alters the increase in IL-16 level in adult immune thrombocytopenia

Zuo Xinyi Qilu Hospital, Shandong University, Department of Hematology, Jinan, China

O1-05 A novel murine model of immune thrombocytopenia induced by immunized CD41-knockout mice

Li Xin Qilu Hospital of Shandong University, China

O1-06 Neutrophil activation by heparin induced thrombocytopenia antibodies is required for thrombus formation

Leung Halina HL University of New South Wales, Australia

O1-07 Pharmacokinetic profile of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgery

Kushimoto Shigeki Tohoku University Graduate School of Medicine, Japan

Oral Communication 2 - Platelets and Cardiovascular Disorders

10:00 - 11:00

Chair: Yutaka Yatomi Department of Clinical Laboratory, The University of Tokyo Hospital, Japan

Jiaan-Der Wang Rare Disease and Hemophilia Center, Taichung Veterans General Hospital, Taiwan

Program - June 29 (Fri.)

- O2-01 Growth arrest-specific gene 6 receptors, Tyro3, Axl, and Mer, differentially participate in platelet activation and thrombus formation**
Zhou Junsong The Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, First Affiliated Hospital, Soochow University, China
- O2-02 Familial platelet disorder with predisposition to myeloid malignancy (FPDMM); atypical phenotypes of *RUNX1* gene variants**
Ward Christopher Royal North Shore Hospital, Sydney, Australia
- O2-03 Recombinant Thrombomodulin (rTM) Reduced Neutrophil Extracellular Trap (NET) Formation and Improved Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis in Murine Models**
Watanabe Kanako Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan
- O2-04 High-molecular-weight kininogen improves host defense during Gram-negative sepsis**
Yang Aizhen Soochow University, China
- O2-05 Targeted microbubbles loaded with microRNA for a theranostic approach of abdominal aortic aneurysms**
Wang Xiaowei Baker Heart and Diabetes Institute, Australia
- O2-06 Kallistatin-Sirtuin 1 pathway is crucial in limiting abdominal aortic aneurysm progression**
Krishna Smriti M James Cook University, Australia
- O2-07 Nanoliposomes for Safe and Efficient Therapeutic CD39 mRNA Delivery: Prevention and Treatment of Inflammatory and Cardiovascular Diseases**
Wang Xiaowei Baker Heart and Diabetes Institute, Australia

Oral Communication 3 - Platelets

13:20 - 14:30

- Chair:** Kenji Yokoyama Department of Hematology and Oncology, Tokai University Hachioji Hospital, Japan
Robert Medcalf Monash University, Australia
- O3-01 NLRP3 regulates platelet integrin α IIb β 3 outside-in signaling, hemostasis and arterial thrombosis**
Qiao Jianlin Xuzhou Medical University, China
- O3-02 Migfilin regulates hemostasis and thrombus formation through affecting platelet α IIb β 3 outside-in signaling.**
Zhou Yangfan Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, China
- O3-03 Induced pluripotent stem cells from Bernard Soulier syndrome patients as a disease model to study the mechanisms of macrothrombocytopenia**
Mekchay Ponthip Inter-Department Program of Biomedical Sciences, Faculty of Graduate School, Chulalongkorn University, Thailand
- O3-04 The transmembrane thiol isomerase TMX1 is a strong negative regulator of platelet function**
Zhao Zhenzhen Soochow University, China
- O3-05 A role of Pyk2 in regulation of platelet shape change downstream of $G_{12/13}$ pathways**
Chaudhary Preeti K Chungbuk National University, Republic of Korea
- O3-06 Platelet Peroxisome Proliferator-activated Receptor α is involved in hemostasis and thrombus formation**
Wang Shuai Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, China

Program - June 29 (Fri.)

O3-07 Characterization of a Heparin-Independent Monoclonal Antibody that Causes Heparin-Induced Thrombocytopenia

Perdomo Jose University of New South Wales, Australia

O3-08 Establishing an integrated diagnostic pathway for suspected platelet bleeding disorders

Connor David St Vincent's Centre For Applied Medical Research, Australia

Oral Communication 4 - Hemophilia

14:30 - 15:30

Chair: Satoshi Higasa Hyogo College of Medicine, Japan

Ming-Ching Shen Department of Internal Medicine, Changhua Christian Hospital, Taiwan

O4-01 Achievement of normal factor VIII activity following gene transfer with valoctocogene roxaparvovec (BMN 270): Long-term efficacy and safety results in patients with severe hemophilia A

Pasi John Barts and the London School of Medicine and Dentistry, United Kingdom

O4-02 The origin and occurrence of de novo mutation in hemophilia A without prior family history

Shen Ming-Ching Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan

O4-03 Influence of Genetic Polymorphisms of Biological Mediators on the Phenotypic Heterogeneity in Hemophilic Arthropathy

Chen Yeu-Chin Hemophilia care & research center, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan

O4-04 FVIII Gene Mutation In Paediatric Severe Haemophilia A With Inhibitors And Respond To Immune Tolerance Induction. A Single Centre

Faraizah Abdul Karim NATIONAL BLOOD CENTER KUALA LUMPUR, Malaysia

O4-05 Discrepancies between the results of one-stage clotting assays and the chromogenic assay in hemophilia A patients

Nagao Azusa Ogikubo Hospital, Department of Blood Coagulation, Japan

O4-06 Use of the HEAD-US in a Haemophilia Treatment Centre

Piper Kristen Royal Prince Alfred Hospital, Australia

O4-07 Low-dose ITI strategy for high-titer inhibitor hemophilia A children with poor ITI risk in China

Li Zekun Beijing Children's Hospital, Capital Medical University, China

Oral Communication 5 - Transfusion and Monitoring

15:30 - 16:30

Chair: Kohji Okamoto Kitakyushu Municipal Yahata Hospital, Japan

Ross Baker Western Australia Centre for Thrombosis and Haemostasis (WACTH) Murdoch University, Australia

O5-01 Alterations of plasma miRNA 122 and its correlation with other hematologic variables in patients undergoing repeated phlebotomy

Adiyanti Sri Suryo Clinical Pathology Department, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo Hospital, Indonesia

O5-02 Knowledge, Attitude and Practice of Blood Donation among First Year Medical Students at the Faculty of Medicine and Surgery of the University of Santo Tomas

Garcia Angelita T. University Of Santo Tomas Hospital, Philippines

O5-03 Knowledge, Attitudes And Practices On Blood Transfusion Of Medical Residents In A Tertiary Hospital: A Questionnaire-Based Study

Miranda Rmin Sheila J. University of the Philippines - Philippine General Hospital, Philippines

Program - June 29 (Fri.)

- O5-04 Comparison between Japanese obstetrical DIC score and the pregnancy modified ISTH DIC score for obstetric DIC cases**
Nitta Satoshi Department of Obstetrics and Gynecology, Tokyo Metropolitan Bokutoh Hospital, Japan
- O5-05 The Strength of ABO Blood Typing in Patients with Incompatibility Crossmatch**
Dalimoenthe Nadjwa Zamalek
Dr Hasan Sadikin Hospital Bandung Indonesia, Indonesia
- O5-06 Monitoring of Anticoagulation for Adults Undergoing Cardiopulmonary Bypass in Cardiac Surgery**
Zhang Yang Center of Laboratory Medicine, National Center for Cardiovascular Diseases & Fuwai Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China
- O5-07 Monitoring treatments by unfractionated heparin (UFH). Stability of plasma anti-Xa activity for up to 4 hours in citrated tubes**
Toulon Pierre Pasteur University Hospital, France

Master Class

16:40 - 17:30

Chair: Masahiro Ieko Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Japan

How to perform good coagulation assays

Steve Kitchen Department of Coagulation, Royal Hallamshire Hospital, UK

Royton Hall CD (3F)

Poster Session 1 - Atherothrombosis

17:30 - 18:30

- P1-01 A novel microRNA 145-embedded stent for suppression of post-angioplasty restenosis in a rabbit model**
Che HuiLian Department of Genomic and Precision Medicine, Wuxi School of Medicine, Jiangnan University, China
- P1-02 Anti- β_2 GPI antibodies enhance atherosclerosis in ApoE-deficient mice**
Zhou Hong School of Medicine, Jiangsu University, China
- P1-04 The Polymorphisms of Transcriptional Binding Site in *PAI-1* Promotor associated with Coronary Artery Disease**
Park Han Sung Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Republic of Korea
- P1-05 Serotonin Concentration in Peripheral Blood Reflects Oxidative Stress and Plays a Crucial Role in Atherotic Coronary Artery Disease**
Sugiura Tomonori Nagoya City University Graduate School of Medical Sciences, Japan

Poster Session 1 - Bleeding Disorders I

17:30 - 18:30

- P1-06 Progranulin facilitates the increase of platelet count in immune thrombocytopenia**
Zuo Xinyi Qilu Hospital, Shandong University, Department of Hematology, Jinan, China
- P1-07 Analysis of anti-thrombopoietin receptor antibodies in patients with immune thrombocytopenia**
Satoh Takashi Division of Hematology, Kitasato University School of Allied Health Sciences, Japan
- P1-08 Platelet clearance *in vitro* and *in vivo* in drug-induced immune thrombocytopenia**
Wong Rose St George Hospital, Australia

Program - June 29 (Fri.)

- P1-09 Clinical manifestations and genetic mutations of hereditary hemorrhagic telangiectasia patients seen in middle part of Taiwan**
Lin Ching-Yeh Department of internal medicine, Changhua Christian Hospital, Taiwan
- P1-10 Bullous pemphigoid is a common associated disease with acquired hemophilia A**
Abdul Halim Nurul Aidah Singapore General Hospital, Singapore
- P1-11 Correlation of the ratios of von Willebrand factor (VWF) ristocetin cofactor activity to VWF antigen amount (VWF:RCo/VWF:Ag) with the VWF large multimer levels evaluated with its multimer analysis**
Shingo Sugawara Department of Clinical Laboratory, Tohoku University Hospital, Japan

Poster Session 1 - Coagulant and Anticoagulant I

17:30 - 18:30

- P1-12 Potential application of clot waveform analysis in monitoring Rivaroxaban**
Low Chin Quan National University Healthcare System, Singapore
- P1-13 The rivaroxaban-specific international normalized ratio (INR) of prothrombin time (PT) can synchronize therapeutic effects of rivaroxaban among different laboratories**
Kim Bohyun Department of Laboratory Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea
- P1-14 Clinical Audit of laboratory testing for the Direct Oral Anticoagulants in NSW, Australia**
Ward Christopher M Royal North Shore Hospital, Sydney, Australia
- P1-15 Preoperative activated partial thromboplastin time screening — is it necessary for gynecological surgery**
Yan Lingyi Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, China
- P1-16 Blood coagulation biomarkers for postoperative venous thromboembolism diagnosis in lung cancer patients**
Li Mengyu Department of Laboratory Medicine, West China Hospital, Sichuan University, China
- P1-17 Establishment and clinical significance of reference range of D-dimer, Fibrin/Fibrinogen Degradation Products and antithrombin in pregnant women**
Liu Xiaoyan Obstetrical and Gynecological Hospital of Fudan University, China

Poster Session 1 - Diagnostic Modalities

17:30 - 18:30

- P1-18 Change in Clinical Laboratory Parameters of Patients with Bacteremia**
Tsai Yuhong Chang Gung Memorial Hospital, Chiayi, Taiwan
- P1-19 Indirect Anti-Platelet Antibody Testing in ITP - Diagnostic Method Renewed**
Zheng Shiyong Haematology Research Unit, St. George & Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Australia
- P1-20 Longitudinal evolution of IgM phosphatidylserine-dependent antiprothrombin antibody titers in patients with autoimmune diseases**
Amengual Olga Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
- P1-21 Association study of blood coagulation pathway gene (*CFD*, *CFH* and *EDNRB*) polymorphisms with risk of recurrent pregnancy loss (RPL).**
Kim Eun Gyo Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Republic of Korea
- P1-22 APTT-based Clot Waveform Analysis in Dengue and viral infections**
Chu Miao Hui Yvonne Department of Haematology, Singapore General Hospital, Singapore

P1-23 Performance Evaluation of Innovance Antithrombin, Berichrom Protein C and Innovance Free Protein S reagents using the Automated Coagulation Analyzer Sysmex CS-5100

Park Rojin

Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea

Poster Session 1 - Fibrinolysis and Proteolysis

17:30 - 18:30

P1-24 Macrophage promotes the tissue remodeling and the recovery of liver functions during liver regeneration after carbon tetrachloride-induced liver injury.

Miura Atsushi

Department of Applied Life Sciences, Nihon University Graduate School of Bioresources Sciences, Japan

P1-25 Sphingosine 1-phosphate induced by hypoxia increases the expression of PAI-1 in HepG2 cells via HIF-1 α

Sanagawa Akimasa

Department of Molecular and Cellular Pathobiology and Therapeutics, Graduate School of Pharmaceutical Sciences, Nagoya City University., Japan

P1-26 Functional analysis of a variant fibrinogen from dysfibrinogenemia patient with cerebral infarction

Hattori Yuna

Pathophysiological Laboratory Science, Nagoya University Graduate School of Medicine, Nagoya, Japan

P1-27 Hereditary angioedema caused by a novel type of dysplasminogenemia

Dewald Georg

Institute For Molecular And Preventive Medicine, Germany

P1-28 The diagnostic significance of plasma D-dimer level and platelet aggregation in patients with recurrent spontaneous abortion

Chen Huifen

Shanghai First Maternity and Infant Hospita, China

P1-29 The Correlation between Coagulation-Fibrinolytic System Markers and Clinical Stages and TCM Syndrome Type of Lung Cancer

Chen Wenxin

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, China

Poster Session 1 - Hemophilia I

17:30 - 18:30

P1-30 Comparison of IS-PCR and LD-PCR based Genotyping for Intron 22 Inversion in a Single Center

Yoo Kiyoung

Korea Hemophilia Foundation, Republic of Korea

P1-31 Educational interventions to enhance adherence to prophylactic treatment in Korean hemophilia patients

Choi Eun Jin

Daegu Catholic University Hospital, Republic of Korea

P1-32 Assessment of psychosocial issues in mothers of children with hemophilia

Nakao Aya

Ehime University, Japan

P1-33 Comparison of Perioperative Practices for Placement of Central Venous Access Devices (CVAD) in Paediatric Haemophilia Patients with Inhibitors

Lam Joyce C M

KK Women's and Children's Hospital, Singapore

P1-34 STUDY OF SOME CASES WITH HEMOPHILIA IN HEMOPHILIA A CARRIER IN THE NORTH OF VIETNAM

Nguyen Mai Thi

National Institute of Hematology and Blood Transfusion, Viet Nam

P1-35 The importance of direct telephone communication between doctor and patient to improve the survival in hemophilia patient with life-threatening hemorrhage

Lee Kun Soo

Kyungpook National University School of Medicine, Daegu, Republic of Korea

P1-36 Inhibitor development in a 70 year old patient with previously untreated severe hemophilia A

Tanaka Asashi

Tokyo Medical University Hachioji Medical Center, Japan

Program - June 29 (Fri.)

- P1-38 Haploid origin of unusual Inv22 X-chromosome carrying wild-type telomere region in severe hemophilia A patients**
Kakihara Misaki Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
- P1-39 Role of Thromboelastography in the diagnosis and assessment of clinical severity in hemophilia**
Kurien Annamma Department of Pathology, Melaka Manipal Medical College, Manipal Academy Of Higher Education, Manipal, Karnataka, India
- P1-40 Diagnostic and prognostic value of a novel ELISA system for detection of factor VIII inhibitory antibodies in hemophilias**
Moriyama Masato Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Japan
- P1-41 Prophylaxis with recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) reduces consumption compared with previous FIX in both adult and paediatric patients**
Oldenburg Johannes Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
- P1-42 Long-term safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with haemophilia B: an ongoing phase 3b extension study**
Seifert Wilfried CSL Behring, Marburg, Germany
- P1-43 Management of simultaneous major bleeding from acquired haemophilia (AH) and deep vein thrombosis: A therapeutic dilemma**
Fan Bingwen Eugene Tan Tock Seng Hospital, Singapore
- P1-44 Efficacy and safety of bolus infusions of rFVIII-Fc during the perioperative bleedings in two patients with hemophilia A.**
Yamasaki Naoya Division of Blood Transfusion, Hiroshima University Hospital, Japan
- P1-45 Long-acting recombinant Factor IX in Surgical Prophylaxis for Haemophilia B: A Single Centre Experience**
Abd Karim Faraizah National Blood Centre, Malaysia

Poster Session 1 - Immunity

17:30 - 18:30

- P1-46 NLRP3 inflammsome activation in PBMCs controls the CD4+ T cell response in adult patients with chronic immune thrombocytopenia**
Hua Mingqiang Qilu Hospital, Shandong University, China
- P1-47 Histone-induced neutrophil extracellular traps is suppressed by recombinant thrombomodulin**
Shrestha Binita Kagoshima University, Japan
- P1-48 Plasmablast Proliferation is Associated with Toll Like Receptor 7 Polymorphisms, Contributing to the Autoantibody Production in Antiphospholipid Syndrome**
Hisada Ryo Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan
- P1-49 Increased proportion of Th17/Treg T cells for early prediction of chronic immune thrombocytopenia in children.**
Gu Hao Beijing Children Hospital, Capital Medical University, China

Poster Session 1 - Laboratory Issues I

17:30 - 18:30

- P1-50 Lack of Correlation Between Heparin Dose and Coagulation Assays in Paediatric Extracorporeal Membrane Oxygenation - A Single Institution Experience**
Ang Soh Hong KK Women's and Children's Hospital, Singapore
- P1-51 Clinical and Laboratory Evaluation of Persistent Antiphospholipid Antibody Positivities**
Han Jin-Yeong Department of Laboratory Medicine, Dong-A University College Of Medicine, Republic of Korea
- P1-52 Lupus anticoagulant hypoprothrombinemia syndrome in childhood: a case report**
Kershaw Geoffrey Royal Prince Alfred Hospital, Australia
- P1-53 Little Effect of Lupus Anticoagulant on Prothrombin Time and activating Partial Thromboplastin Time: A Real-World Observation**
Lee Min Young Asan Medical Center, Republic of Korea
- P1-54 Application of thromboelastography in trauma patients**
Kim Moon Jung Seonam University College of Medicine, Republic of Korea
- P1-55 Value of Preoperative Activated partial Thromboplastin Time Test as a Predictor for Surgical Hemorrhage of Chinese Pregnant Patients**
Cui Yali Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, China
- P1-56 Rotatory Thromboelastometry (Rotem®) versus Disseminated Intravascular Coagulation Score as the Predictors of Bleeding in Dengue Infection**
Natesirinilkul Rungrote Faculty of Medicine, Chiang Mai University, Thailand
- P1-57 Management the Big Data of Laboratory Medicine by Infographic Tools**
Tsai YuHong Department of Laboratory Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan

Poster Session 1 - Management of Thromboembolism I

17:30 - 18:30

- P1-58 Lack of standardization of the anti-factor Xa activity and the anti-factor Xa-correlated aPTT therapeutic ranges used in the monitoring of unfractionated heparin (UFH)**
Toulon Pierre Pasteur University Hospital, Nice, France
- P1-59 Optimal International Normalized Ratio Range for Asian Patients on Anticoagulation Therapy in Singapore**
Kong Ming Chai Singapore General Hospital, Singapore
- P1-60 A rivaroxaban - outpatient deep vein thrombosis (DVT) treatment pathway in an Emergency Department Observational Unit in Singapore**
Teo Winnie ZY Department of Haematology-Oncology, National University Cancer Institute, Singapore
- P1-61 RISK FACTORS OF POST THROMBOTIC SYNDROME**
Ariyanti Farieda Department of internal Medicine, Medical Faculty Indonesia University/Cipto Mangunkusumo Hospital, Indonesia
- P1-62 Clinical features of inferior vena cava thrombosis**
Lin Shyuann-Yuh Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
- P1-63 Antiphospholipid Score is a Novel Risk Factor for Idiopathic Osteonecrosis of the Femoral Head**
Kato Masaru Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan
- P1-64 The impact of endothelial marker on catheter ablation in patients with atrial fibrillation.**
Namino Fuminori Clinical Laboratory, Kagoshima University Hospital, Japan

Program - June 29 (Fri.)

- P1-65 A case of successful balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension**
Akasaka Kazumi Asahikawa Medical University Hospital, Medical Laboratory and Blood Center, Japan
- P1-66 Acute Myeloid Leukemia presenting as ST-elevation Myocardial Infarction and Acute Limb Ischemia: A Case Report and Review of Literature**
Vaswani Preeti Prerna M. Philippine General Hospital, Philippines
- P1-79 National survey of thromboembolism patients among Japanese users of female hormones**
Sugiura Kazuko Department of Reproductive Health Nursing/Midwifery, Nagoya City University Graduate School of Nursing, Japan

Poster Session 1 - Platelets - Basic

17:30 - 18:30

- P1-67 Antiplatelet effect on megakaryocyte differentiation and tumor-bearing mice**
Wang Jiaan-Der Center for Rare Disease and Hemophilia, Taiwan
- P1-68 Platelets after long-term splenectomy: Deficiency of key platelet-specific surface receptors and platelet activation suggest a role in increased thrombogenicity**
Luu Sarah Australian Centre for Blood Diseases, Australia
- P1-69 BML-260, a DUSP22 inhibitor, limits Collagen-induced platelet activation via the impediment to tyrosine phosphorylation of Syk**
Jiang Peng Institute of blood transfusion, CAMS/PUMC, China
- P1-70 VerifyNOW and Multiplate analysis of Low dose Ticagrelor Treated Patients with Acute Coronary Syndromes in Korean Population**
Park Nuree Laboratory of Clinical Research Center, Asan Institute for Life Science, Republic of Korea
- P1-71 Attenuation of platelet activation and thrombus formation by tannic acid: inhibition of protein disulfide isomerase**
You Tao Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, China
- P1-72 Indirubin modulates T cell function via PD1/PTEN/Akt-dependent signaling in ITP**
Zhao Yajing Department of Hematology, Qilu Hospital, Shandong University, China
- P1-73 SSRI Suppresses Platelet Activation via Collagen Receptor.**
Sugita Naoko Kyoto University, Japan
- P1-74 Remote ischaemic pre-conditioning (RIPC) stabilises platelet mitochondrial function and reduces procoagulant platelet formation in coronary artery disease (CAD) patients**
Liang Helena ANZAC Research Institute, Concord Hospital, Australia
- P1-75 HNG, a potent humanin analog, stabilizes platelet microtubules and protects against thromboinflammatory myocardial injury by targeting β 1-tubulin**
Ren Lijie Soochow University, China
- P1-76 A novel stat3 inhibitor Inhibits tumour cell-induced platelet aggregation**
Chong Kowit-Yu Chang Gung University Department of Medical Biotechnology and Laboratory Science, Taiwan
- P1-77 Disabled-2 Ser24 phosphorylation is involved in outside-in signaling of integrin in human platelets**
Tsai Hui-Ju Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan, Taiwan
- P1-78 TUBB1 mutation identified by whole genome sequencing interferes microtubule assembly in a Chinese family with congenital macrothrombocytopenia**
Hou Yu Qilu Hospital, Shandong University, China

Royton Hall AB (3F)

Special Lecture 2

11:10 - 12:00

Chair: Tatsuya Atsumi Faculty of Medicine, Internal Medicine, Hokkaido University Hospital, Japan

Neutrophil extracellular traps and autoimmunity and vasculopathy

Mariana J. Kaplan Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, USA

Heine's Hall (2F)

Morning Symposium (CSL Behring Asia Pacific Ltd.)

Perspectives on Advances in Haemophilia Management

7:50 - 8:50

Chair: Midori Shima Department of Pediatrics, Nara Medical University, Japan

Clinical Experience in Transitioning Patients to Afstyla and Idelvion

Johannes Oldenburg Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn AöR, Germany

Clinical Trial Experience - Surgical Management

Faraizah Bt Dato' Abdul Karim National Blood Centre, Kuala Lumpur, Malaysia

Symposium 3

Antithrombotic therapies in Asia 2018: current status and future perspective

9:00 - 11:00

Chair: Mitsuru Murata Department of Laboratory Medicine, Keio University School of Medicine, Japan

Jameela Sathar Ampang Hospital, Malaysia

Direct Oral Anticoagulants in Ischemic Heart Disease

Youngkeun Ahn Department of Cardiology, Chonnam National University Hospital, Korea

How to estimate the risk of recurrent venous thromboembolism

Hun-Gyu Hwang Respiratory Division, Department of Internal Medicine, Soonchunhyang University Gumi Hospital, South Korea

Is the best antithrombotic strategy for Asian patients different from the other regions of the world?

Shinya Goto Department of Medicine, Tokai University School of Medicine, Japan

Antithrombotic therapies in Asia 2018: current status and future perspective

Sui Huang Institute of hematology, Union hospital, Huazhong University of Science & Technology, China

Luncheon Symposium (Sysmex Corporation)

12:10 - 13:10

Chair: Katsuyuki Fukutake Laboratory Medicine, Tokyo Medical University, Japan

Issues of diagnosis and monitoring for haemophilia patients.

Steve Kitchen Department of Coagulation, Royal Hallamshire Hospital, UK

Program - June 30 (Sat.)

Symposium 4

Bench to bedside research harnesses the power to combat bleeding disorders

14:10 - 16:10

Chair: Tadashi Matsushita Department of Transfusion Medicine, Nagoya University Hospital, Japan
Ching-Tien Peng Department of Pediatric Hematology & Oncology, China Medical University, Taiwan

A Bispecific Antibody, Emicizumab, Mimicking Factor VIII: A Novel Alternative Therapy for Patients with Hemophilia A

Keiji Nogami Department of Pediatrics, Nara Medical University, Japan

Diagnostic approaches in bleeding disorders

Liane Khoo Haematology Department, Royal Prince Alfred Hospital, Australia

CRISPR/Cas9-mediated Genome Editing for Hemophilia B by AAV Vector

Tsukasa Ohmori Department of Biochemistry, Jichi Medical University, Japan

Bench to Bedside Research Harnesses the Power to Combat Bleeding Disorders

Thynn Thynn Yee Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, UK

Crystal Room C (2F)

APSTH / JSTH Joint Symposium

Time to reappraise cutting-edge basic science to further reduce thrombotic risk

9:00 - 11:00

Chair: Yujiro Asada Department of Pathology, Faculty of Medicine, University of Miyazaki, Japan
Christopher Ward Royal North Shore Hospital, Australia

Spatiotemporal analysis of membrane surface-based fibrinolysis on vascular endothelial cells and activated platelets

Yuko Suzuki Department of Medical Physiology, Hamamatsu University School of Medicine, Japan

Discovering Novel Anticoagulants from Nature

Mark Y. Chan National University Heart Centre, Singapore

Procoagulant platelets: a potential new target in thrombosis

Vivien M.Y. Chen Haematology, Concord Hospital, Australia

Development of Novel Drug-Eluting Stents for Acute Myocardial Infarction

Myung Ho Jeong Department of Cardiovascular Medicine, Chonnam National University Hospital, Korea

Luncheon Symposium (Spark Therapeutics, Inc.)

12:10 - 13:10

Chair: Leonard A. Valentino Spark Therapeutics, U.S.A.

Recombinant Adeno-associated virus (AAV): A transformative biotechnology for gene augmentation

Leonard A. Valentino Spark Therapeutics, U.S.A.

Keiya Ozawa Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Japan

Oral Communication 6 - Management of Thromboembolism

14:10 - 15:00

Chair: Teruto Hashiguchi Laboratory and Vascular Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Japan

Lugyanti Sukrisman Bayer Indonesia, Indonesia

O6-01 Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone

Shin Junghoon Seoul National University Hospital, Republic of Korea

Program - June 30 (Sat.)

06-02 The Promotion and Exploration of Venous Thromboembolism Prevention and Treatment System and Caprini Risk Model in the Area of Leshan, Sichuan Province

Yi Qun Department of Respiratory and Critical Care Medicine of West China Hospital, Sichuan University, China

06-03 Early thrombosis of the portal venous system after splenectomy for thalassemia major

Nguyen Tuan Minh Children's Hospital 1, Viet Nam

06-04 Morbidity and mortality in patients with antiphospholipid syndrome: a longitudinal cohort study of Japanese patients

Fujieda Yuichiro Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University, Japan

06-06 An investigation of hypofibrinogenemia and decreased antithrombin levels in the post-marketing surveillance of recombinant human thrombomodulin for disseminated intravascular coagulation

Wada Hideo Mie University, Japan

06-07 Venous thromboembolism in Asia and worldwide: Emerging insights from the GARFIELD-VTE registry

Angchaisuksiri Pantep Ramathibodi Hospital, Mahidol University, Thailand

Oral Communication 7 - Clinical Hemostasis and Thrombosis

15:10 - 16:10

Chair: Hisanori Horiuchi Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Japan

Soo Mee Bang Seoul National University, Korea

07-01 Clinical relevance of testing IgM phosphatidylserine-dependent antiprothrombin antibodies

Amengual Olga Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

07-02 Successful International Standardised Study of ADAMTS13 Assays - Results from the Asia-Pacific Microangiopathic Thrombocytopenia (APMAT) Network

Baker Ross I Western Australia Centre for Thrombosis and Haemostasis (WACTH) Murdoch University, Australia

07-03 Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and TM in disseminated intravascular coagulation Fa multi-center prospective observational study

Mei Heng Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

07-04 The effect of bacterial infection on APTT-based clot waveform analysis

Lim Shan Shan Haematology Department, Singapore General Hospital, Singapore

07-05 The comparison between fibrin monomer complex and soluble fibrin reagents in thrombosis markers from the view of fibrinolysis proceeding situation

Kumano Osamu Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Japan

07-06 The combination of Caprini risk assessment scale and thrombosis biomarkers for evaluating the risk of venous thromboembolism in critically ill patients

Fu Yang West China Hospital, Sichuan University, China

07-07 Antiphospholipid scoring is predictive for the development of atherosclerosis in systemic lupus erythematosus patients.

Ohmura Kazumasa Department of Internal Medicine, Health Sciences University of Hokkaido, Japan

Program - June 30 (Sat.)

Royton Hall CD (3F)

Poster Session 2 - Bleeding Disorders II

13:10 - 14:10

- P2-01 Increased Expression of Glutaminase in B lymphocytes in patients with immune thrombocytopenia (ITP).**
Wang Qi The First Affiliated Hospital of Soochow University, China
- P2-02 Plasma Profile of Platelet Auto-antibodies in Patients with Thrombocytopenia in Pregnancy**
He Yang Jiangsu Institute of Hematology, China
- P2-03 Acquired Glanzmann thrombasthenia due to marked reduction of surface $\alpha\text{IIb}\beta\text{3}$ expression with non function-blocking anti- $\alpha\text{IIb}\beta\text{3}$ antibodies**
Akuta Keigo Osaka University Graduate School of Medicine, Department of Hematology and Oncology, Japan
- P2-04 A case of congenital coagulant factor V deficiency that has been disclosed after the incidents of repeated postpartum hemorrhage**
Nishioka Kazuhiro Yamatotakada Municipal Hospital, Japan
- P2-05 When the Platelet Count Doesn't Count**
Zheng Shiyang Silvia Haematology Research Unit, St. George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales, Australia
- P2-06 Quantitative analysis of VWF large multimers may predict bleeding risk in patients with aortic stenosis**
Tsuyoshi Doman Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Japan

Poster Session 2 - Coagulant and Anticoagulant II

13:10 - 14:10

- P2-07 Reversal of anticoagulation in patients on rivaroxaban or apixaban (DOAC) with major bleeding episodes (MBE) with 4 factor prothrombin complex concentrate (PCC): a retrospective study**
Fan Bingwen Eugene Tan Tock Seng Hospital, Singapore
- P2-08 Real-world experience with idarucizumab reversal of dabigatran in 3 Australian health districts**
Ward Christopher Royal North Shore Hospital, Sydney Australia, Australia
- P2-09 The relationship between serum zinc level and sepsis-induced coagulopathy**
Irie Yuhei Division of Emergency and Critical Care Medicine, Fukuoka University Hospital, Japan
- P2-10 Evaluating the Safety and Effectiveness of Enoxaparin in Patients with Renal Impairment**
Shim Yuan Tying Singapore General Hospital, Singapore
- P2-11 Neutrophil Extracellular Traps are Associated with Hypercoagulability in Pancreatobiliary Malignancies**
Gu Ja-Yoon Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
- P2-12 Patients with Nephrotic Syndrome and Factor X Deficiency Should be Evaluated for Amyloidosis : A report of case**
You Eunyoung Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Poster Session 2 - Hemophilia II

13:10 - 14:10

- P2-13 Research on Bone Transformation Index and changes of Bone Mineral density of Hemophilia Patients**
Yan Zhenyu North China University of Science and Technology Affiliated Hospital, China
- P2-14 Successful Excision of Limb Pseudotumor in a Severe Hemophilia Patient Treated with Low-dose Radiotherapy Prior to Combined Bolus and Continuous Intravenous Factor Replacement: A Case Experience**
de Castro Joy Ann V. University of Santo Tomas Hospital Manila, Philippines
- P2-15 Various complications after vascular procedure in hemophilia patients**
Park Young Shil Kyung Hee University Hospital at Gangdong, Republic of Korea
- P2-16 Long-term outcomes of patients with acquired Hemophilia A**
Tan Melinda SY Singapore General Hospital, Singapore
- P2-17 Underlying malignancy found in acquired Hemophilia A patients with severe bleeding: A Report of 2 Cases**
You Eunkyong Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- P2-18 Challenging bleeding and thrombosis management in patients with von Willebrands disease: 2 case reports**
Khoo Liane Royal Prince Alfred Hospital, Sydney, Australia
- P2-19 Acquired Haemophilia A in Myanmar: Ten-year experience at a single center (YGH)**
Win Sein Department of Clinical Haematology, Yangon General Hospital, University of Medicine (1), Yangon, Myanmar
- P2-20 Therapeutic Approach to Hemophilia Patients with Non-Traumatic Central Nervous System Bleed**
de Castro Joy Ann V. University of Santo Tomas Hospital Manila, Philippines
- P2-21 Combined deficiency of factors V and VIII caused by chance coinheritance of parahemophilia and hemophilia A (the second report); Evaluations on clotting assay parameters and clinical symptom.**
Suzuki Sachiko Department of Pathophysiological Sciences, Nagoya University Graduate School of Medicine, Japan
- P2-22 Determining the cutoff value of mixing test for factor VIII inhibitor**
Tang Ning Tongji Hospital, Huazhong University of Science and Technology, China
- P2-23 Evaluation of employing a commercially available ELISA system as routine laboratory tests for the measurement of factor VIII inhibitory antibodies in a patient with congenital hemophilia A**
Matsuda Masato Medical Laboratory Division, Niigata University Medical and Dental Hospital, Japan
- P2-24 High observed and steady-state trough FIX activity levels are maintained with recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) prophylaxis in haemophilia B patients**
Seifert Wilfried CSL Behring, Marburg, Germany
- P2-25 Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: Efficacy and safety in previously treated Korean patients**
Young Shil Park Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea
- P2-26 Low dose immune tolerance induction (ITI) in haemophilia A adults with inhibitors**
Cheong May Anne Singapore General Hospital, Singapore
- P2-27 Sub analysis of Japanese Patients with Hemophilia A in rVIII-SingleChain clinical trial**
Higasa Satoshi Hyogo College of Medicine, Japan

Program - June 30 (Sat.)

- P2-28 Long-acting recombinant fusion protein linking factor IX with albumin (rIX-FP) in Surgical Prophylaxis for Haemophilia B: A Single Centre Experience**
Shahidan Mazidah National Blood Centre, Malaysia

Poster Session 2 - Laboratory Issues II

13:10 - 14:10

- P2-29 Genetic and functional analyses of two protein C gene mutations on healthy Japanese young women**
Noguchi Kenta Graduate School of Health and Nutritional Sciences, Nakamura Gakuen University, Japan
- P2-30 Establishment of the immature platelet fraction (%IPF) reference interval using the Sysmex XN-9000 haematology analyzer**
Wong Wan Hui Singapore General Hospital, Singapore
- P2-31 The association study of microRNAs polymorphisms (*miR-605A>G*, *miR-608G>C*, *miR-631I>D*, *miR-938C>T*, and *miR-1302-3C>T*) with risk of Recurrent Implantation Failure (RIF).**
Kim Eun Gyo Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Republic of Korea
- P2-32 Simultaneous assay of Free and total protein S using monoclonal antibodies by a fully automated analyzer**
Kaneko Makoto Department of Clinical Laboratory, University of Yamanashi Hospital, Japan
- P2-33 Apixaban and rivaroxaban assay stability after 24 hours of sample storage in the primary collection tube**
Kershaw Geoffrey Royal Prince Alfred Hospital, Australia
- P2-34 Samples with in vitro haemolysis should be rejected for APTT but can be analysed with Innovin for PT/INR.**
Woolley Anita Sheffield Haemophilia and Thrombosis Centre, United Kingdom
- P2-35 Validation study of two point-of-care testing devices (Coaguchek® Pro II and Coaguchek® INRange) against standard venous sampling of the International Normalised Ratio**
See Edmund Joo Sheng Singapore General Hospital, Singapore
- P2-36 Pilot study of pre-analytical sample integrity checks to detect interfering substance using an automated coagulation analyzer ACL TOP 350 CTS (IL, USA)**
Tae Eun Jeong Seosan Medical Center, Republic of Korea
- P2-37 Evaluation of CS-5100 in Platelet aggregation test: Comparison with Chrono-log aggregometer**
An Gyu-Dae Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Republic of Korea
- P2-38 Immature Platelet Fraction in Children with Thrombocytopenia**
Sirachainan Nongnuch Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

Poster Session 2 - Management of Thromboembolism II

13:10 - 14:10

- P2-39 MEAN PLATELET VOLUME (MPV) AS A PREDICTOR OF VENOUS THROMBOEMBOLISM (VTE) IN COLORECTAL CANCER**
Wilasrusmee Chumpon Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
- P2-40 Perioperative Coagulofibrinolytic Responses in Colorectal Surgery**
Matsumoto Hironori Department of Gastrointestinal Surgery and Surgical Oncology, Ehime University Graduate School of Medicine, Japan

- P2-41 Dual antiplatelet therapy as the treatment option for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome**
Ohnishi Naoki Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
- P2-42 Safe Childbirth for a Type 1 Antithrombin-deficient Patient Undergoing Antithrombin Concentrate Therapy**
Ikeda Yuichi Ehime University Graduate School of Medicine, Japan
- P2-43 The Proportion of Aspirin Resistance in Type II Diabetes Mellitus in Indonesia**
Setiabudy Rahajuningsih Dharma Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Indonesia
- P2-44 Clinical features and treatment outcome of cerebral sinovenous thrombosis in Taiwanese children with acute lymphoblastic leukemia**
Chen Shih-Hsiang Division of Pediatric Hematology/Oncology, Chang Gung Memorial Hospital, Taiwan
- P2-45 Short and mid-term treatment results of Edoxaban against emergency case of elderly patients with non-valvular atrial fibrillation in Japanese one common hospital.**
Masaya Kainuma Otemae Hospital, Japan
- P2-46 Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 9 cases report of children**
Yixuan He Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, China
- P2-47 Two cases of peripherally inserted central catheter related venous thrombosis: utility of vascular ultrasound was verified**
Akasaka Kazumi Asahikawa Medical University Hospital, Medical Laboratory and Blood Center, Japan

Poster Session 2 - Pathogenesis of Thromboembolism

13:10 - 14:10

- P2-48 MARBURG I POLYMORPHISM (G511E) IN ADULTS PATIENTS WITH DEEP VEIN THROMBOSIS**
Kumar Narender Postgraduate Institute of Medical Education and Research, Chandigarh, India
- P2-49 Seasonal Variation in Pulmonary Embolism but Not Deep Vein Thrombosis Incidence: A Korean Nationwide Venous Thromboembolism Epidemiology Study**
Hong Junshik Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Republic of Korea
- P2-50 Hypercoagulable State in Patients with Non-Hodgkin Lymphoma**
Moonla Chatphatai Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- P2-52 Deep Vein Thrombosis and Pulmonary Embolism in a Girl with Protein S Deficiency and Inferior Vena Cava Malformation: a case report and literature reviews**
Shih MingYang Center for Rare Diseases and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan
- P2-53 Clot Waveform Analysis in Acute Venous Thromboembolism in Patients With and Without Cancer**
Chua Brian Lee Wei Singapore Health Services, Singapore

Program - June 30 (Sat.)

Poster Session 2 - Platelets - Clinical

13:10 - 14:10

- P2-54 Altered circulating T follicular helper cells in patients with chronic immune thrombocytopenia**
Dai Lan Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, China, 2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- P2-55 Serotonin levels in platelet-poor plasma of patients with coronary vasospastic angina and coronary microvascular dysfunction.**
Hirowatari Yuji Saitama Prefectural University, Japan
- P2-56 Correlation between VerifyNow P2Y12 Reaction Unit, Light transmission aggregometry and Hemoglobin level in Hemodialysis Patients**
Kim Weon Kyung Hee University Hospital, Republic of Korea
- P2-57 Can Neuraminidase Inhibitors be option for treatment of thrombocytopenia?**
Ko Sun-Young Korea University Medical Center, Republic of Korea
- P2-58 A Prospective, Randomized Clinical Trial of High-dose Dexamethasone Combined With Osetamivir Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia F Interim Analysis**
Sun Lu Department of Hematology, Qilu Hospital, Shandong University, China
- P2-59 High-dose dexamethasone versus prednisone for treatment-naïve adult primary immune thrombocytopenia: A Real-World Study**
Wang Liang Department of Hematology, Qilu Hospital, Shandong University, China
- P2-60 Acute ischemic stroke after use of thrombopoietin receptor agonist in pediatric patient with chronic immune thrombocytopenia: A case report**
Choi Youngha Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Republic of Korea
- P2-61 Treatment Outcomes and Profile of Patients with Immune Thrombocytopenia at a Tertiary Hospital: The TOP-IT Study**
Miranda Rmin Sheila J. University of the Philippines - Philippine General Hospital, Philippines
- P2-62 Efficacy of treatments for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis**
Abe Nobuya Department of Rheumatology, Nephrology and Endocrinology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan
- P2-63 Successful Therapeutic Management and Delivery in a Pregnancy complicated by Secondary Evans Syndrome from Systemic Lupus Erythematosus and concurrent Antiphospholipid Syndrome**
Tanchanco Camille Ariadne Concepcion University Of The Philippines- Philippine General Hospital, Philippines
- P2-64 Rivaroxaban for the treatment of suspected Heparin-induced thrombocytopenia (HIT)**
Ong Shin Y Singapore General Hospital, Singapore

Poster Session 2 - Stroke

13:10 - 14:10

- P2-65 ACE and KDR Ins/Del Polymorphisms Contributed to Ischemic Stroke Susceptibility and Post-Stroke Mortality.**
Park Han Sung Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Republic of Korea
- P2-66 Correlation between residual platelet reactivity and postoperative ischemic symptoms in patients with Moyamoya disease administered aspirin**
Yamazaki Masako Department of Neurology, Tokyo Women's Medical University, Japan

Poster Session 2 - Transfusion Medicine

13:10 - 14:10

- P2-67 The effect of adding platelet rich plasma to fibrin glue on release of platelet growth factors and stability of fibrin glue in body fluids**
 Chuansumrit Ampaiwan Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
- P2-68 Regular Protein C Replacement Prevents Purpura Fulminans in Severe Congenital Protein C Deficiency**
 Lim Chiew Ying KK Women's And Children's Hospital, Singapore
- P2-69 The effect of Fresh Frozen Plasma Storage to Factor VIII activities in Blood Bank**
 Delita Prihatni Dept/KSM of Clinical Pathology Faculty of Medicine Universitas Padjadjaran Dr. Hasan Sadikin General Hospital Bandung, Indonesia, Indonesia

Poster Session 2 - Vascular Biology and Medicine

13:10 - 14:10

- P2-70 Plasminogen binding to its receptor thrombomodulin to promote vascular endothelial growth factor secretion and cutaneous wound healing**
 Wu Hua-Lin National Cheng Kung University, Taiwan
- P2-71 Plasma fibroblast growth factor 23 level is associated with plasma levels of high-sensitivity cardiac troponin I, T and echocardiographic left ventricular hypertrophy.**
 Ito Atsushi Asahikawa Medical University, Japan
- P2-72 The role of IL-13 in regulating pulmonary artery endothelial cell migration**
 Yamakuchi Munekazu Kagoshima University School of Medical and Dental Sciences, Japan
- P2-73 Persistent Endothelial Activation in Thalassemia Disease after Hematopoietic Stem Cell Transplantation**
 Sitthirat Peerasit Department of Biology, Mahidol Wittayanusorn School, Nakhon Pathom, Thailand
- P2-74 Circulating microRNA-4688 Reflects Oxidative Stress and may Serve as a Novel Biomarker of Functional and Atherosclerotic Coronary Artery Disease**
 Sugiura Tomonori Nagoya City University Graduate School of Medical Sciences, Japan
- P2-75 Comparison with multimeric distribution of VWF secreted from HUVECs and BOECs stimulated by PMA**
 Ma Zhenni MOH Key Lab Of Thrombosis And Hemostasis, Jiangsu Institute Of Hematology, The First Affiliated Hospital Of Soochow University, China
- P2-76 Development of a sustainable and stable ischemia by sequential ischemia induction in a novel two-stage lower limb ischemia model**
 Smriti Murali Krishana The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, School of Medicine and Dentistry, James Cook University, Australia
- P2-77 Molecular Determinants of Functional and Fibrotic Changes by Novel Automated Oscillometric Approach to Measure Brachial Artery Vascular Volume Elastic Modulus**
 Yoshinaga Keiichiro National Institute of Radiological Sciences, Japan
- P2-78 Measurements of brachial artery cross-sectional vascular area and volume elastic modulus using automated oscillometric measurements: reproducibility between examiners, and intra-rater reliability**
 Ito Kasumi Medical Laboratory and Transfusion Center, Asahikawa Medical University Hospital, Japan
- P2-79 Breast Cancer Associated Thrombotic Microangiopathy: A Case Report and Review of Literature**
 Vaswani Preeti Prerna M. Philippine General Hospital, Philippines